AVTX vs LEN · P/E 0.0, rev $441.0K vs rev $34.19B
Avalo Therapeutics Inc (AVTX) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
LEN (LEN) common stock.
Latest reported AVTX revenue for 2024-12-31 was $441.0K. Net income was -$35.1M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. LEN currently screens at market cap $0.
Not investment advice. Open the AVTX and LEN stock pages for the full models.
Not investment advice.